Droplet Biosciences, a diagnostics company developing lymph-based liquid biopsy tests, announced on Tuesday a collaboration with NVIDIA Corp (NASDAQ:NVDA) to detect residual cancer within 24 hours of surgery, weeks earlier than traditional blood-based monitoring.

By pairing lymphatic fluid analysis with GPU-accelerated genomics tools from Nvidia, the company has also sharply reduced computational turnaround times.

•NVIDIA shares are experiencing downward pressure. Why is NVDA stock trading lower?

A New Timeline For Residual Cancer Detection

Unlike conventional minimal residual disease (MRD) tests that rely on blood plasma weeks after surgery, Droplet collects lymphatic fluid just 24 hours after tumor removal.

According to Wendy Winckler, chief scientific officer at Droplet Biosciences, the fluid contains significantly higher concentrations of tumor-derived DNA because it is sourced near the tumor site rather than diluted in circulating blood.

The company reports that post-surgical lymphatic fluid holds 130 times more ...